Lineage Cell Therapeutics
LCTX
109 hedge funds and large institutions have $151M invested in Lineage Cell Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
71% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 21
14% more funds holding
Funds holding: 96 → 109 (+13)
1.33% more ownership
Funds ownership: 48.18% → 49.51% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $161M → $151M (-$9.94M)
27% less call options, than puts
Call options by funds: $112K | Put options by funds: $153K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.71M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$582K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$488K |
| 4 |
Two Sigma Investments
New York
|
+$441K |
| 5 |
IA
IndexIQ Advisors
New York
|
+$438K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$1.8M |
| 2 |
Millennium Management
New York
|
-$362K |
| 3 |
Jane Street
New York
|
-$223K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$196K |
| 5 |
Goldman Sachs
New York
|
-$181K |
LCTX Hedge Fund Activity: Q2 2017 in Review
109 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2017, worth a combined $151M — down 6.2% from $161M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LCTX positions and 7 closed out — a net gain of 13 holders — while 36 added to existing stakes and 21 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.71M. The largest seller was Northern Trust, cutting an estimated $1.8M.
- 109 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2017, up from 96 in Q1 2017.
- Funds reported $151M of Lineage Cell Therapeutics stock for Q2 2017, down 6.2% quarter-over-quarter.
- 20 funds opened new Lineage Cell Therapeutics positions in Q2 2017 and 7 closed out, a net change of +13 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2017 was Vanguard Group, an estimated $1.71M added.
- The largest Lineage Cell Therapeutics seller in Q2 2017 was Northern Trust, an estimated $1.8M sold.
Based on aggregated 13F filings for Q2 2017.